Generic Rebetol meeting
Executive Summary
Three Rivers Pharmaceuticals meets with FDA Chief Counsel Daniel Troy to discuss "labeling issues" for generic version of Schering-Plough's Rebetol (ribavirin) June 24. Three Rivers expects 2003 launch for the generic...
You may also be interested in...
Generic Ribavirin Labels Will Carve Out Rebetol/PEG-Intron Indication
Three Rivers Pharmaceuticals is amending its ribavirin ANDA to remove references to an 800 mg dose appearing in Schering-Plough's Rebetol labeling
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.